Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis and HIV news

Show

From To
Two interferon-free regimens show high HCV cure rates for people with HIV and HCV co-infection

A pair of two-drug, 12-week regimens containing neither interferon nor ribavirin – sofosbuvir (Sovaldi) plus either ledipasvir (the Harvoni coformulation) or daclatasvir (Daklinza) – cured hepatitis

Published
10 hours ago
By
Liz Highleyman
NICE guidance recommends sofosbuvir (Sovaldi, Gilead Sciences) and simeprevir (Olysio, Janssen) for treating hepatitis C

Following a request from NHS England and consultation with stakeholders, the period during which NHS England has to comply with the recommendations for sofosbuvir is extended to 31 July 2015. The period during which NHS England has to comply with the recommendations for simeprevir has not been extended.

Published
26 February 2015
From
NICE press release
New hepatitis C treatments highly effective for HIV/HCV coinfected people

A pair of interferon-free combinations -- AbbVie's 3-drug Viekira Pak regimen and Gilead Science's sofosbuvir/ledipasvir (Harvoni) -- demonstrated good safety and cured more than 90% of genotype 1 HIV/HCV coinfected people, according to studies published in the February 23 advance edition of the Journal of the American Medical Association.

Published
26 February 2015
From
HIVandHepatitis.com
Sexual Transmission of HCV in Gay Men Should Not Be a PrEP Deterrent, Say Advocates

After two men on pre-exposure prophylaxis (PrEP) at the Kaiser Permanente San Francisco Medical Center tested positive for the hepatitis C virus (HCV), clinicians at the center penned a letter to the editor of the journal Clinical Infectious Diseases calling for routine HCV testing in gay men who are currently on PrEP. The two men were among 485 HIV-negative gay men receiving PrEP at the clinic between 2011 and 2014.

Published
26 February 2015
From
The Body
Clinicians report two acute HCV infections in Kaiser San Francisco PrEP programme

Two HIV-negative gay men receiving HIV pre-exposure prophylaxis (PrEP) through Kaiser Permanente in San Francisco were newly infected with hepatitis C virus (HCV), with sex being their only

Published
22 February 2015
By
Liz Highleyman
Cost-Effectiveness of Immediate Hepatitis C Treatment in Early Disease Analyzed

For patients with hepatitis C virus (HCV), immediate treatment seems to be cost-effective in those with moderate and advanced fibrosis, and can be cost-effective in patients with no or minimal fibrosis, according to a study published online Feb. 11 in Hepatology.

Published
20 February 2015
From
HCP Live
amfAR Report Examines Controversial Pricing of Hepatitis C Treatment

The new amfAR report, titled “Hepatitis C and Drug Pricing: The Need for a Better Balance,” urges structural changes that alter the pricing incentives for pharmaceutical companies in such a way that they cannot charge exorbitant prices for their products, however effective they may be.

Published
19 February 2015
From
amfAR
The Drug That Is Bankrupting America

With a rational U.S. drug pricing system, private investors would expect to earn a reasonable multiple of their R&D for a highly successful drug, perhaps even 5 to 10 times the R&D outlays, in order to reflect the long time horizons and high uncertainties surrounding drug development. Yet at a treatment course of $84,000, the multiple for Sovaldi looks to be around 40 times or more.

Published
18 February 2015
From
Huffington Post
Study: Door-to-door campaign linked hepatitis C patients to care

Working on the streets in medically underserved Philadelphia neighborhoods, members of the Do One Thing program have been able to identify residents chronically infected with hepatitis C and help them overcome the hurdles that prevent people from being cured, according to a new study in the Journal of General Internal Medicine.

Published
16 February 2015
From
Eurekalert Inf Dis
Healthcare: The race to cure rising drug costs

The controversy over hepatitis C drug prices has highlighted the broader question of whether pharmaceutical companies can defend their premium pricing model in the world’s biggest healthcare market. It is a battle that big pharma risks losing, raising questions over the economic model of an industry that relies heavily on US profits to reward investors and finance new drugs.

Published
13 February 2015
From
Financial Times
← First12345...158Next →

Filter by country